Viking Recalibrates Drug Focus In New IPO Plans
California-based Viking Therapeutics Inc. revived its initial public offering plans Monday after taking its postponed $60 million debut back to the drawing board, now focusing on a drug to ease rehabilitation...To view the full article, register now.
Already a subscriber? Click here to view full article